26th May 2015 06:12
LONDON (Alliance News) - AstraZeneca PLC said Tuesday that Amgen Inc has terminated their co-development and commercialisation deal for monoclonal antibody brodalumab after observing "suicidal ideation and behaviour events" in the programme that might result in "restrictive labelling".
Brodalumab was developed by Amgen and was in development for moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The two companies entered into a collaboration deal in April 2012 for five monoclonal antibodies from Amgen's clinical inflammation portfolio, including brodalumab.
AstraZeneca said it will confirm its decision on the future development of brodalumab as soon as possible based on further review of the data.
"Data from the three AMAGINE Phase III pivotal studies highlighted that brodalumab has an effective mechanism of action that delivers clinical benefit. We will fully evaluate the data and assess all options before we make our independent decision about the future of this potential medicine," said Briggs Morrison, executive vice president, global medicines development and chief medical officer at AstraZeneca in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca